other material
confidence high
sentiment positive
materiality 0.80
Cel-SCI reports Multikine Phase 3 biomarker data: 20% 5-year OS benefit in low PD-L1 head & neck cancer patients
CEL SCI CORP
- Low PD-L1 subgroup (TPS<10) showed 20% absolute 5-year overall survival advantage for Multikine+SOC vs SOC alone (60% vs 40% alive).
- PD-L1 low subgroup represents >70% of lower-risk patients; hazard ratio 0.68 for LR population all patients.
- Data suggest potential to combine Multikine with checkpoint inhibitors like Keytruda or Opdivo for broader coverage.
- Company filed patent for Multikine use in tumors with low PD-L1 expression.
- Previously reported 14.1% absolute 5-year OS benefit in lower-risk ITT patients; now biomarker confirms effect.